SEC Comment Letter for Alaunos Therapeutics, Inc. (TCRT) (CIK 0001107421) (TCRT) — Aug 19, 2022
Alaunos Therapeutics, Inc. (TCRT) (CIK 0001107421)
Date: Aug. 19, 2022 · CIK: 0001107421 · Accession: 0000000000-22-008920
AI Filing Summary & Sentiment
File numbers found in text: 333-266841
Letter
United States securities and exchange commission logo August 19, 2022 Kevin Boyle, Sr. Chief Executive Officer Alaunos Therapeutics, Inc. 8030 El Rio Street Houston, TX 77054 Re:Alaunos Therapeutics, Inc. Registration Statement Filed on Form S-3 Filed August 12, 2022 File No. 333-266841 Dear Mr. Boyle: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Melinda Lackey
Show Raw Text
United States securities and exchange commission logo
August 19, 2022
Kevin Boyle, Sr.
Chief Executive Officer
Alaunos Therapeutics, Inc.
8030 El Rio Street
Houston, TX 77054
Re:Alaunos Therapeutics, Inc.
Registration Statement Filed on Form S-3
Filed August 12, 2022
File No. 333-266841
Dear Mr. Boyle:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Melinda Lackey